Aptose to Report Third Quarter 2022 Financial Results and Hold Conference Call on Tuesday, November 1, 2022GlobeNewsWire • 10/18/22
Aptose Strengthens Board of Directors with Appointment of Bernd R. Seizinger, M.D.GlobeNewsWire • 09/13/22
Aptose to Present at the H.C. Wainwright 24th Annual Global Investment ConferenceGlobeNewsWire • 08/30/22
Aptose Biosciences Inc. (APTO) CEO William Rice on Q2 2022 Results - Earnings Call TranscriptSeeking Alpha • 08/03/22
Aptose to Report Second Quarter 2022 Financial Results and Hold Conference Call on Tuesday, August 2, 2022GlobeNewsWire • 07/19/22
Aptose Appoints Fletcher Payne as Senior Vice President, Chief Financial OfficerGlobeNewsWire • 06/27/22
Aptose Biosciences Inc. (APTO) CEO Dr. William G. Rice on Q1 2022 Results - Earnings Call TranscriptSeeking Alpha • 05/10/22
Aptose Receives Fast Track Designation for HM43239 in Relapsed/Refractory AML Patients and FLT3 MutationGlobeNewsWire • 05/04/22
Luxeptinib Preclinical Data Extend Potential Applications from Oncology to InflammationGlobeNewsWire • 05/02/22
Aptose to Report First Quarter 2022 Financial Results and Hold Conference Call on Monday, May 9, 2022GlobeNewsWire • 04/25/22
Aptose to Present at Canaccord Genuity's 2022 Horizons in Oncology Virtual ConferenceGlobeNewsWire • 03/31/22
Aptose Biosciences Inc. (APTO) CEO Dr. William G. Rice on Q4 2021 Results - Earnings Call TranscriptSeeking Alpha • 03/23/22